Hmmm...why isn't TEVA jumping all over this? It seems to me that they could even reformulate Azilect with ECGC and market it as truly neuroproctive. This study sounds way more conclusive than the recent ADAGIO delayed start research that showed conflicting results. In fact, this study rather supports the ADAGIO finding that Azilect was neuroprotective at 1 mg only (no benefit for people at 2 mg).

I have a stash of Azilect samples in my hall closet. I had to stop taking it due to joint pain side effect; the White Rat in me is oh so tempted to now experiment with this.

Also wonder how this low, below therapeutic dose finding relates to the DX and Naltrexone approach to neuroprotection?

Laura